Portfolio company
KDTB Research
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
KDTB Research develops antibiotics for patients with tuberculosis and non-tuberculous mycobacterial infections.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
C10 PHARMA
This biopharmaceutical company develops novel antibiotics to treat life-threatening bacterial infections and combat antimicrobial resistance for patients with unmet medical needs.
Adjutecpharma
This company develops antibiotic resistance breakers for healthcare providers to treat patients with life-threatening bacterial infections.
AdjutTec
This pharmaceutical company develops antibiotic resistance breakers to treat patients with multidrug-resistant bacterial and fungal infections.
Amprologix
This biotechnology company develops novel antibiotics to treat antimicrobial-resistant bacterial infections for patients with conditions including MRSA and related skin and wound infections.
Achaogen
Achaogen develops antibacterial treatments for multi-drug resistant infections to serve patients with limited or no alternative treatment options.
Discuva
This biotechnology company develops novel antibiotics to treat multi-drug resistant bacterial infections for pharmaceutical partners and healthcare providers.
Nabriva
This biopharmaceutical company develops and commercialises novel antibiotics for patients with serious infections caused by drug-resistant bacteria.
Arpida
This company develops antimicrobial drugs and broad-spectrum antibiotics to treat patients with severe bacterial infections requiring hospital treatment.